RxDoctor Payments Data

Richard Lewis, MD

Ophthalmology · Tucson, AZNPI 1952570889

Payments from drug & device makers

$894in general payments, 2019–2025

Across 46 payments — averaging $19.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$209
  • Aerie Pharmaceuticals, Inc.$167
  • AbbVie$162
  • Amgen$106
  • Tarsus Pharmaceuticals, Inc.$61
  • Sight Sciences, Inc.$56
  • plus $133 from 5 others

What the payments were for

  • Food & beverage$87698%
  • Education$182%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$894 in reported general payments places this provider in the 35th percentile of 310 ophthalmology providers in Arizona.

See all ophthalmology providers in Arizona

Medicare billing

Part B allowed, 2024
$364,715
Medicare patients
2,097
Services billed
3,582

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost143$89,923
RestasisCyclosporine62$83,318
XiidraLifitegrast64$66,480
RocklatanNetarsudil Mesylat/Latanoprost85$63,685
Cyclosporine45$33,922
CombiganBrimonidine Tartrate/Timolol35$12,074
RhopressaNetarsudil Mesylate24$9,988
Travoprost50$7,629
Latanoprost584$5,465
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol39$5,403
Prednisolone Acetate149$4,842
ValacyclovirValacyclovir Hcl42$3,606
SimbrinzaBrinzolamide/Brimonidine Tart14$2,819
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat150$2,291
Timolol Maleate128$1,371

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$162$185,316240 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$167$73,673109 claims
Bausch & Lomb Americas Inc.Xiidra$53$66,48064 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 310 ophthalmology providers in Arizona.

Other ophthalmology in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →